The MS Family Study
Researchers from the Menzies Institute for Medical Research are seeking participants who come from families with multiple relatives affected by multiple sclerosis (MS). By analysing the genetic code of such families, the researchers want to better understand the inherited risk of MS.
ACT-Sydney Multiple Sclerosis (MS) cohort study
As part of the Our Health in Our Hands (OHIOH) project, researchers at the Australian National University and Sydney Adventist Hospital are working together to improve the clinical management and overall health and wellbeing of people living with multiple sclerosis (MS). In this study we are recruiting people with MS as well as people who […]
A clinical trial for patients with Myelin oligodendrocyte glycoprotein antibody disorder (MogAD)
This is a Global, Multicentre Phase III, Randomised, Double-Blind Clinical Trial. The study currently includes over 120 adults and is actively recruiting adolescents (12-18 years of age) with MOGAD from around the world. In Australia 3 sites are participating in the study, located in NSW.
Anxiety in Multiple Sclerosis
We are interested in identifying psychological factors that contribute to the development and maintenance of anxiety in individuals with MS. We are also interested in comparing these factors to those without an illness. Participants will be requested to fill out an online questionnaire at three different time points. Time 1: Fill out an ~30min questionnaire. […]
MS Genetics Project (GEMS Study)
We need your help to investigate the Epstein-Barr Virus (EBV) strain that may play a crucial role in developing multiple sclerosis (MS). This study also aims to identify specific markers in the blood associated with onset and progression of MS. The knowledge gained will be used to greatly improve MS diagnosis, treatment and prevention.
Assisted Reproductive Technology in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders (ARTiMS)
The purpose of this study is to improve the quality of care that women with Multiple Sclerosis (MS) or Neuromyelitis Optica Spectrum Disorder (NMOSD) receive while using Assisted Reproductive Technology (ART). We’re inviting women with MS or NMOSD who have already used ART to take part in surveys and interviews to discuss if and where […]
The interaction between diet, physical activity and sleep with neuroplasticity in people with multiple sclerosis
Dietary intake, physical activity levels and sleep vary between individuals, but how do these factors influence the central nervous system, and does this differ between people with and without multiple sclerosis? This study will aim to address these questions via collecting dietary intake, physical activity and sleep data, and using non-invasive brain stimulation during cycling […]
Reducing the frequency of Autoimmune adverse events in the treatment of Multiple sclerosis with alemtuzumab using B-celL dEpletion (RAMBLE): a phase II, randomised, placebo-controlled clinical trial
To reduce the occurrence of autoimmune adverse events from the treatment of multiple sclerosis (MS) with alemtuzumab through the subsequent targeted use of rituximab. The hypothesis to be tested is that rituximab therapy following alemtuzumab treatment for MS will reduce the frequency of autoimmune adverse events. If this strategy proves to be safe and is […]
The QUEST initiative: QUality of life Evaluation STudy: Assessing Health Related Quality of Life in patients receiving medicinal cannabis
You are invited to take part in a research study exploring quality of life and health economic impacts in patients accessing medicinal cannabis. People accessing medicinal cannabis may have a range of conditions and symptoms that impact their quality of life. We would like to know how these conditions and symptoms impact quality of life […]
Autologous Haematopoietic Stem Cell Transplantation for highly active treatment resistant multiple sclerosis
We propose to study the benefits and risks of Autologous Haematopoetic Stem Cell Transplant (AHSCT) in people who have an aggressive form of MS not controlled by conventional treatment. Participants will have AHSCT at The Alfred hospital, and they will be closely monitored for 5 years post the transplant to ensure their safety, and also […]